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ABSTRACT 
Pancreatic β-cell expansion throughout the neonatal period is essential to generate the appropriate 
mass of insulin-secreting cells to maintain blood glucose homeostasis later in life. Hence, defects 
in this process can predispose to diabetes development at adulthood. Global profiling of the 
transcripts in pancreatic islets of newborn and adult rats revealed that the expression of the long 
non-coding RNA H19 is controlled by the transcription factor E2F1 and is profoundly 
downregulated during the post-natal period. H19 silencing decreased newborn β-cell expansion 
while its re-expression promoted proliferation of adult β-cells via a mechanism involving the 
microRNA let-7 and the activation of Akt. The offspring of rats kept on a low protein diet during 
gestation and lactation display a reduced β-cell mass and an increased risk to develop diabetes at 
adulthood. We found that the islets of newborn rats born from dams on a low protein diet express 
lower levels of H19. Moreover, we observed that H19 expression raises in the islets of obese 
mice under conditions of increased insulin demand. Taken together, our data suggest that the 
lncRNA H19 plays an important role in postnatal rat β-cell mass expansion and contributes to the 
mechanisms compensating for insulin resistance under obesity conditions.  
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INTRODUCTION        
Pancreatic β-cells, located within the islets of Langerhans, maintain blood glucose levels in a 
physiologically relevant range by precisely adapting insulin secretion to circulating levels of 
nutrients, particularly glucose (1). Insulin-secreting cells acquire a fully differentiated phenotype 
only after birth. Before weaning neonatal β-cells produce and release insulin in response to amino 
acids but the capacity to secrete insulin in response to a rise in glucose levels, a characteristic 
feature of fully mature β-cells, is still missing (2; 3).  
Another hallmark of newborn β-cells is a strong proliferative capacity that allows a massive 
expansion of the number of insulin-secreting cells during the postnatal period. After weaning, the 
replication slows down to maintain a more or less constant β-cell mass during the entire life (4). 
Defective β-cell expansion early in life can result in an insufficient mass of insulin-secreting cells 
at adulthood, predisposing the individuals to the development of diabetes. Under conditions 
associated with increased metabolic demands, such as pregnancy and obesity, β-cells raise their 
secretory activity and their replication rate.  Failure to compensate for insulin-resistance linked to 
pregnancy or obesity can lead to hyperglycemia and eventually to the onset of gestational or type 
2 diabetes, respectively (5). 
So far, most studies investigating the mechanisms driving postnatal β-cell maturation focused on 
protein-coding genes. However, the advent of high throughput RNA sequencing revealed that 
most genome sequences generate RNA molecules which are not coding for proteins (6). We now 
know that the non-coding transcriptome is involved in multiple biological processes influencing 
development, differentiation and metabolism (7-9). Emerging evidence points to a role for non-
coding RNAs also in postnatal β-cell maturation. Indeed, we showed that the nutritional shift at 
weaning from a fat-rich mother milk to a carbohydrate-rich chow diet triggers vast changes in the 
microRNA (miRNA) profile of newborn β-cells that are instrumental for the acquisition of 
glucose responsiveness and of a mature secretory phenotype (10).  
Beside small non-coding RNAs, the mammalian transcriptome includes a large number of long 
non-coding RNAs (lncRNAs) containing more than 200 nucleotides (11-13). Recently, thousands 
of lncRNAs were identified in human and mouse pancreatic islets (14-16). Many of these 
lncRNAs are specifically expressed in islets and are induced during β-cell differentiation. These 
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findings suggest a role for lncRNAs in developmental programming, proper functioning and/or 
maintenance of pancreatic islet cells.  
The aim of this project was to identify lncRNA-based mechanisms that contribute to the 
acquisition of the mature β-cell phenotype and that control the size of the functional β-cell mass. 
Screening for lncRNAs differentially expressed during islet postnatal maturation revealed the 
downregulation of H19, a maternally imprinted intergenic lncRNA generated from the Igf2 locus 
(17). We provide evidence indicating that H19 contributes to β-cell mass expansion in newborn 
rats and is re-expressed in adult islets under conditions of increased insulin demand. Moreover, 
we show that the level of H19 is lower in the islets of pups born from dams kept on a low protein 
diet during gestation and lactation, and which display a reduced β-cell mass and increased risk to 
develop diabetes at adulthood. Our findings provide new insights into the role of H19 in newborn 
and adult rodent β-cells and unveil a potential mechanism explaining the increased diabetes 
susceptibility of the offspring of mothers kept on deleterious dietary conditions during pregnancy 
and lactation. 
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RESEARCH DESIGN AND METHODS 
Chemicals 
IL-1β, hexadimethrine bromide, histopaque 1119 and 1077 were obtained from Sigma-Aldrich 
(St. Louis, MO). 3-isobutyl-1-methylxanthine (IBMX) was purchased from Merck (Whitehouse 
Station, NJ, USA), IFN-ɣ from R & D Systems (Minneapolis, MN, USA) and TNF-α from Enzo 
Life Sciences (Farmingdale, NY, USA).  
Animals 
Three month old male Sprague Dawley rats were purchased from Janvier Laboratories (Le 
Genest-Saint-Isle, France). P1 to P31 pups were obtained by collecting the offspring of pregnant 
Sprague Dawley rats. Pregnant Wistar rats were fed during gestation and lactation with a control 
diet (20% [w/w] protein) or an isocaloric low protein diet (8% [w/w] protein) (Hope Farm, 
Woerden, the Netherlands) (18). 13-16 week old C57BL/KsJ db/db and C57BL/6J ob/ob mice 
and age-matched lean control mice (db/+ C57BL/KsJ or -/- C57BL/6J, respectively) were taken 
from the Garvan Institute breeding colonies. 5-week old C57BL/6 male mice (Charles River 
Laboratories, Raleigh, NC, USA) were fed with a normal (ND) or a high-fat diet (HFD) for 8 
weeks (Bioserv F-3282, 60% energy from fat, Frenchtown, NJ, USA). The mice that after 7.5 
weeks on HFD weighed between 33 and 39 g were classified as low responders (LDR), while 
those weighing between 39 and 45 g were defined as high responders (HDR). Weight, glycemia 
and insulinemia of these animals were reported previously (19).  
Microarray profiling 
RNA was isolated from pools of islets of 5 P10 pups from 3 different mothers and 3 individual 
adult rats. mRNA and lncRNA profiling using the Rat lncRNA Array v2.0 and data analysis were 
carried out by Arraystar (Rockville, MD, USA). Differentially expressed transcripts were 
identified through Volcano Plot filtering (fold change ≥2, nominal p ≤0.05). The data are 
available on the GSE106919 record using the secure token: qfolagkublsfrov. 
Culture of INS832/13 and 1.1B4 cells 
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The rat β-cell line, INS832/13 was kindly provided by Dr. C. Newgard (Duke University, USA)  
and was cultured as described (20). The cells were seeded at a density of 4x104/cm2 for 
immunocytochemistry and cell death assessment, at 7.5x104/cm2 for insulin secretion and 
1.1x105/cm2 for RNA isolation. The human β-cell line 1.1B4 was generously provided by Dr. P. 
Flatt (University of Ulster) and was cultured as described (21).  
Isolation and culture of islet cells 
Rat pancreatic islets were isolated by collagenase digestion (22), purified on a Histopaque density 
gradient and then cultured as described (10). Islet cells were dissociated by trypsinization and 
seeded at a density of 5x104/cm2 for immunocytochemistry and 105/cm2 for RNA isolation.
Fluorescence activated cell sorting  
Dissociated islet cells from newborn and adult rats were sorted by FACS based on β-cell 
autofluorescence (23). Immunocytochemistry analysis using anti-insulin antibodies (#A0564, 
Dako, Basel, Switzerland) showed that 94 ± 1% of the cells in the purified fraction were insulin-
positive. 
Cell transfection 
Overexpression was achieved by transfecting a pcDNA3 plasmid harboring the sequences of the 
lncRNA using Lipofectamine 2000TM (Invitrogen, Carlsbad, CA) in INS832/13 cells or 
Lipofectamine 3000TM (Invitrogen) in islet cells. Downregulation was obtained by transfecting 
siRNAs against GFP (Eurogentec, Seraing, Belgium), H19 (Thermo Fisher Scientific, Waltham, 
MA, USA), Ago2 or E2f1 (GE Healthcare Europe) or miRCURY LNA™ microRNA Inhibitors 
(anti-miRs) (Exiqon, Bedvaek, Denmark) using Lipofectamine 2000TM (INS832/13 cells) or 
Lipofectamine RNAiMAX TM (Invitrogen) (islet cells). 
RNA isolation and detection 
RNA was isolated with the miRNeasy kit (Qiagen, Basel, Switzerland) for islet cells and with the 
ZR RNA MiniPrepTM kit (Zymo Research, Irvine, CA) for INS832/13 cells. The samples were 
treated with DNase (Promega, Madison, WI, USA) prior to retro-transcription using the M-MLV 
reverse transcriptase, RNAse H minus (Promega). For quantification of lncRNAs and mRNAs, 
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Real-time PCR was performed using iQ SYBR Green mix. LncRNA and mRNA primers are 
provided in the supplemental table 1. For miRNA quantification, Real-time PCR was carried out 
using the miRCURY LNATM Universal RT microRNA PCR kit (Exiqon).  
Immunocytochemistry 
Glass coverslips were coated with poly-L-lysine alone for dissociated islet cells or together with 
laminin for INS832/13 cells.  The cells were fixed with cold-methanol and permeabilized with 
PBS supplemented with 0.5% (v/v) saponin (Sigma-Aldrich). The coverslips were incubated in 
blocking buffer (PBS supplemented with 0.5% (v/v) saponin and 1% (w/v) BSA (Sigma-Aldrich) 
and then exposed to primary antibodies at the following dilutions: 1:700 rabbit anti-Ki67 
(#ab15580, Abcam, Cambridge, UK) and 1:500 guinea pig anti-insulin (#A0564, Dako). After 
washing, the coverslips were incubated with goat anti-rabbit Alexa-Fluor-488 or goat anti-guinea 
pig Alexa-Fluor-555, diluted at 1:500 (#A11008 and #A21435 respectively, ThermoFisher 
Scientific). Finally, they were incubated with Hoechst 33342 (Invitrogen), mounted on glass 
slides and visualized with a Zeiss Axiovision fluorescence microscope. For BrdU 
immunocytochemistry, the cells were incubated for 48h with BrdU (#ab142567, Abcam). After 
exposure to blocking buffer and prior exposure to mouse anti-BrdU antibody (1:400, #BD55627, 
BD Biosciences), DNA was denatured with 2N HCl. BrdU-positive cells were visualized with a 
goat anti-mouse Alexa-fluor-555 antibody (1:500; #A21422 ThermoFisher Scientific). Examples 
of Ki67 and BrdU positive cells are provided in Supplementary Fig.1. At least 1000 cells were 
analyzed for each condition.  
Insulin secretion 
Insulin secretion from INS832/13 cells was carried out as described previously (10). 
Cell death assessment 
INS832/13 cells were washed with PBS and incubated with Hoechst 33342 1µg/ml. The fraction 
of cells displaying pycnotic nuclei was scored after visualization under fluorescence microscopy 
(AxioCam MRc5, Zeiss).  As a positive control for apoptosis, a fraction of cells were exposed 
during 24h to a combination of cytokines (TNF-α 10 ng/ml, IL-1β 0.1 ng/ml, IFN-ɣ 30 ng/ml). 
About 500 cells were counted for each condition. 
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Protein extraction and western blotting 
INS832/13 cells were washed in cold PBS and incubated for 15min in lysis buffer (20 mM Tris, 
pH 7.5, 2 mM EDTA and protease inhibitors (Roche)). The cells were then scraped, briefly 
sonicated and centrifuged to eliminate nuclei and cell debris. 30µg of proteins were loaded on 
acrylamide gels and transferred to polyvinylidine fluoride membranes. The membranes were 
placed for 1h in blocking buffer (0.1% (v/v) Tween 20 and 5% (w/v) BSA followed by overnight 
incubation at 4˚C with primary antibodies diluted in blocking buffer. The antibodies used were 
the following: Rabbit anti-phospho-Akt, 1:500 (Thr308 (#9275S) or Ser473 (#4060S), Cell 
Signaling, Danvers, MA, USA); mouse anti-Akt, 1:500 (#2920, Cell Signaling); mouse anti-actin 
α, 1:15000 (#MAB1501, Merck & Cie, Schaffhausen, Switzerland). After one hour exposure at 
room temperature to horseradish peroxidase-coupled secondary antibodies, 1:15000, (Anti-Rabbit 
IgG (#111-165-144) and anti-mouse IgG (#111-165-166), Jackson ImmunoResearch Europe Ltd., 
Suffolk, UK) immunoreactive bands were visualized by chemiluminescence (ThermoFisher 
Scientific) using the ImageQXSuant LAS-4000 System.   
Luciferase assay 
The luciferase construct with eight let-7 target sites in the 3’UTR of the Renilla gene was a gift 
from Yukihide Tomari (psiCHECK2-let-7 8x; Addgene plasmid # 20931). Luciferase activity 
was measured using a dual luciferase reporter assay (Promega, Madison, WI, USA) and was 
normalized to the Firefly activity generated by the same plasmid. 
Statistical analysis 
Data are means ±SEM. Statistical significance was tested by unpaired or one sample Student’s t 
test when two sets of data were analyzed and by one-way ANOVA followed by multiple 
comparison tests (Dunnet’s or Tukey’s) or Kruskal-Wallis with multiple comparison test (Dunn), 
when the experiments included more than two groups. H19 expression and phenotypic 
characteristics of the mice were correlated by linear regression, using F-test (Graphpad statistical 
package, La Jolla, CA). 
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RESULTS 
To assess the contribution of lncRNAs to the acquisition of a fully differentiated β-cell 
phenotype, we used a microarray to search for lncRNAs differentially expressed between adult 
and neonatal rat islets (ten days after birth, P10). The array includes 5496 lncRNAs, 896 of which 
were upregulated and 1018 downregulated during islet maturation (fold change ≥2; nominal p-
value ≤0.05) (GSE106919, Fig.1a). We decided to investigate in more detail the role of lncRNAs 
displaying the largest expression changes and, to avoid possible interferences from protein-
coding genes, we focused exclusively on intergenic lncRNAs. Interestingly, the expression of 
H19 (NR_027324), a lncRNA generated from a maternally imprinted locus, was 303 times lower 
in the islets of adult compared to those of newborn rats (Fig.1b). These findings were confirmed 
by RT-PCR in whole islets (Fig.1c) and in FACS-purified β-cells (Fig.1d). A time course 
spanning the postnatal period showed that the expression of H19 is highest between P1 and P5 
and strongly decreases thereafter (Fig.1e). 
Several transcription factors can regulate the expression of H19. The level of one of these, E2F1, 
is reduced both in islets (Fig.1c) and purified β-cell (Fig.1d) upon postnatal maturation and 
displays an expression pattern that follows that of H19 (Fig.1e). Silencing of E2F1 in P10 islets 
(Supplementary Fig.2a) resulted in the downregulation of H19 (Fig.1f), suggesting that this 
transcription factor contributes to the control of H19 expression during the postnatal period. In 
contrast, silencing of c-Myc, a transcription factor that regulates H19 expression in other cell 
types (24; 25) and which is downregulated upon β-cell maturation had no effect on the level of 
this lncRNA (Supplementary Fig.3).     
To elucidate the role of H19, we first investigated its function in the rat β-cell line INS832/13. 
Overexpression of H19 to reach levels comparable to those measured in neonatal islets 
(Supplementary Fig.4a), led to an increase in proliferation (Fig.2a) without effects on cell 
survival measured by scoring the pycnotic nuclei (Fig.2b) or by TUNEL assay (Supplementary 
Fig.5). The rise of H19 did also not affect insulin content or secretion (Fig.2c and d). Neonatal rat 
β-cells display a much higher proliferation rate compared to adult β-cells (10). To assess whether 
H19 contributes to postnatal β-cell expansion, the level of this lncRNA was reduced by RNA 
interference (Supplementary Fig.2b). Silencing of H19 in neonatal β-cells resulted in a profound 
decrease in proliferation both when assessed by scoring the number of Ki67+ (Fig.2e) and of 
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BrdU+ cells (Supplementary Fig.6). Moreover, restoration in adult rat islets of elevated levels of 
the lncRNA (Supplementary Fig.4c), induced a four-fold increase in the proliferating β-cells 
(Fig.2f). These effects were independent from Igf2 the levels of which were unchanged by the 
modulation of H19 expression (Supplementary Fig.7). Similar results were obtained upon 
overexpression of human H19 in the human β-cell line 1.1B4 (21) (Supplementary Fig.8). 
H19 has been proposed to exert its action by affecting the level or the activity of different 
miRNAs (26-28). To investigate whether the regulation of β-cell proliferation is mediated by 
miRNAs, we assessed the effect of H19 in cells in which the expression of Argonaute 2 (Ago2), a 
component of the RNA-induced silencing complex (RISC) that is essential for miRNA action 
(29), is reduced by RNA interference (Supplementary Fig.2c). We observed that H19-induced 
proliferation is lost in INS832/13 cells lacking Ago2 (Fig.3a), indicating that H19 action may be 
mediated by miRNAs. 
Two miRNAs, miR-675-5p and 3p, are produced upon processing of H19 (30). Indeed, 
overexpression of H19 in INS832/13 cells (Fig.3b and c) led to corresponding changes in the 
level of these miRNAs and silencing of H19 (Fig.3d and e), resulted in a decrease in miR-675-5p 
expression. Moreover, the expression profiles of these miRNAs throughout the postnatal period 
revealed a downregulation that parallels that of H19 (Fig.3f), suggesting that the effect of the 
lncRNA on β-cell proliferation may be mediated by these miRNAs. To assess this hypothesis, we 
transfected P5 islet cells with anti-miRs to block miR-675-5p or miR-675-3p (Supplementary 
Fig.9a and b). As shown in Fig.3g, while silencing of H19 reduced β-cell proliferation, blockade 
of miR-675-5p or miR-675-3p was without effect, indicating that the action of the lncRNA is 
likely to be independent from these miRNAs. 
H19 expression is induced during myoblast differentiation and has been proposed to sequester the 
miRNA let-7 (31). The expression of most let-7 isoforms is not modified upon islet postnatal 
maturation (10), but possible changes in the repressive activity of these miRNAs have not yet 
been investigated. To evaluate the activity of let-7 in P10 and adult islets we transfected a 
reporter construct containing eight let-7 target sites in the 3’ UTR of the renilla luciferase gene 
(32). We found that the luciferase activity of the let-7 sensor in adult rat islets is reduced 
compared to that of newborn islets, while the activity of a reporter lacking the let-7 target sites 
was not significantly different (Fig.4a), confirming a rise in the activity of let-7 family members 
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after postnatal maturation. Knock-down of let-7a with a specific inhibitor (Supplementary Fig.9c 
and d) led to an increase in proliferation of INS832/13 cells (Supplementary Fig.10). A similar 
tendency was observed in primary adult β-cells but the effect did not reach statistical 
significance, probably because of the presence of several other let-7 isoforms with overlapping 
functions. To circumvent this issue, adult β-cells were transfected with inhibitors targeting 
several let-7 family members (Supplementary Fig.9e). This resulted in a significant increase in β-
cell proliferation (Fig.4b). In view of these findings, we hypothesized that H19 could induce β-
cell proliferation by sequestering let-7, resulting in the de-repression of let-7 targets necessary for 
cell division. Using the RNAhybrid software (33), we identified several potential let-7 binding 
sites in the H19 sequence (Supplementary Fig.11) and generated a mutant lacking the two most 
likely let-7 target sequences (Supplementary Fig.12). To investigate if H19 acts by sequestering 
let-7, we overexpressed wild type and mutant H19 (Supplementary Fig.4b and d) and observed 
that the construct lacking the let-7 binding sites fails to trigger proliferation of INS832/13 and of 
dissociated adult islet cells (Fig.4c and d). These findings suggest that the proliferative effect of 
H19 may be at least in part mediated by preventing the interaction of let-7 with its endogenous 
target(s).  
The PI3K-Akt signaling pathway is a critical regulator of the β-cell mass (34). We measured the 
activation of Akt after overexpression of wild type H19 or of its inactive mutant. We observed an 
increase in Akt phosphorylation after overexpression of wild type H19 but not upon 
overexpression of the inactive mutant (Fig.5a and b). Akt protein levels were unchanged 
(Supplementary Fig.13).  Moreover, blockade of Akt phosphorylation using a pharmacological 
inhibitor (Fig.5c) prevented H19-induced proliferation of INS832/13 cells (Fig.5d) and of 
primary rat β-cells (Fig.5e). Similar results were obtained upon inhibition of PI3K activity with 
LY294002 (Supplementary Fig.14). Taken together, these findings indicate that H19 is likely to 
trigger β-cell proliferation by activating the PI3K-Akt signaling cascade. 
In view of the role of H19 in the control of β-cell proliferation, we investigated whether the 
expression of this lncRNA is modified under conditions associated with changes in the β-cell 
mass. The administration of a low protein (LP) diet to rats during pregnancy has a major impact 
on the offspring, resulting in reduced birth weight, impaired β-cell development and a lower β-
cell mass  (18; 35). These features are associated with an increased risk of impaired glucose 
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tolerance and type 2 diabetes in adult life. We analyzed the expression of H19 and of E2F1 in the 
islets of 10 day-old pups born from mothers kept on control or LP diet. We found that the level of 
both transcripts is reduced in the islets of pups born from rat dams on an LP diet (Fig.6a and b), 
suggesting that altered levels of E2F1 and H19 may contribute to the decrease in β-cell mass in 
the LP offspring. The level of miR-675-5p and miR-675-3p tended also to be reduced but the 
decrease did not reach statistical significance (Fig.6c and d). The let-7a was in contrast slightly 
increased (Supplementary Fig.15), potentially contributing to a reduction in neonatal β-cell 
proliferation.  
Ob/ob mice, which are leptin deficient, become severely obese but remain normoglycemic due to 
a compensatory expansion of their β-cell mass (36; 37). We found that the islets of ob/ob mice 
contain elevated levels of H19 compared to their wild-type littermates (Fig.7a). A similar 
increase in the expression of this lncRNA was also observed in the islets of insulin resistant and 
severely obese db/db mice lacking the leptin receptor and which become diabetic starting at about 
6-8 weeks of age (Fig.7b). Note that an analogous trend of upregulation was found for E2F1 (data 
not shown) (38-40). To assess whether similar changes in H19 expression can be observed under 
conditions of acquired obesity, we measured the level of this lncRNA in the islets of mice fed 
with a high fat diet (HFD) during 8 weeks (19). The animals were classified in two groups 
according to their response to the diet, (i) low responders to HFD (LDR), with mild obesity, 
insulin resistance and normoglycemia, and (ii) high responders to HFD (HDR) with much higher 
obesity, insulin resistance and hyperglycemia, but also with a significant increase in β-cell 
proliferation and β-cell mass (19).  We found H19 and E2F1 levels to be increased in the islets of 
the HDR group (Fig.7c and d).  Moreover, we observed a positive correlation between weight 
gain and H19 levels (Fig.7e).  
Together, our data suggest that in the face of insulin resistance re-expression of H19 may 
contribute to compensatory β-cell mass expansion in adulthood to achieve organismal glucose 
homeostasis. 
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DISCUSSION 
Increasing evidence points to lncRNAs as integral components of the transcriptional machinery 
controlling pancreas development and β-cell function (15; 16; 41; 42). Although some lncRNAs 
have already been functionally linked to islet embryonic development (41) and to the regulation 
of adult β-cell activities (41), so far none of these transcripts has been formally linked to postnatal 
maturation of insulin-secreting cells, a critical process for the acquisition of adult β-cell function. 
A better understanding of the events underlying the maturation of β-cells is needed to unravel the 
developmental origins of diabetes predisposition and would be a leap forward for the engineering 
of functional insulin-secreting cells for the treatment of diabetes. 
In this study, we detected 5496 lncRNAs expressed in newborn rat islets, 896 of which were 
upregulated and 1018 downregulated upon postnatal islet maturation. H19, a lncRNA conserved 
between rodents and humans, is one of the most strongly downregulated transcripts during the 
postnatal period in islet and FACS-sorted β-cells.  
The Igf2/H19 locus plays an important role in embryonic development and growth control (43). 
H19 is highly expressed during embryogenesis and is downregulated after birth in most tissues 
except in skeletal muscle and heart (44). We found that the transcription factor E2F1 is 
downregulated throughout β-cell maturation with kinetics superposing those of H19. E2F 
transcription factors play an important role in regulating cell survival and proliferation (45) and 
E2F1-/- mice display impaired postnatal β-cell proliferation and maturation resulting in an overall 
reduction of pancreatic size and in glucose intolerance at the adulthood (45). Moreover, ectopic 
expression of E2F1 in adult β-cells increases the proliferation of insulin-secreting cells both in 
vitro and in vivo (46). We found that silencing of E2F1 causes a downregulation of H19 in 
immature islets, pointing to a prominent impact of this transcription factor on the control of H19 
expression during the postnatal period. 
Our data indicate that H19 is not involved in the regulation of insulin secretion but affect 
decisively β-cell proliferation. Indeed, silencing of this lncRNA reduces β-cell proliferation in 
newborn rats while restoration of elevated levels of H19 promotes proliferation of adult β-cells. 
This proliferative effect necessitates the activation of Akt and of PI3 kinase but the events 
triggering this signaling pathway remains to be fully elucidated. H19 has been proposed to 
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mediate its effects by modulating the activity of a group of miRNAs, either by sequestering them 
(31), by controlling miRNA maturation  (47), or by directly generating two miRNAs, miR-675-
5p and -3p, encoded in the first exon of the lncRNA (30). The hypothesis of an involvement of 
miRNAs in H19 action is corroborated by the loss of the proliferative capacity of H19 in the 
absence of Ago2, a core component of the RISC complex that is essential for miRNA function 
(29). These findings confirm a role for Ago2 in the induction of β-cell proliferation (48). In these 
experiments we did not observe a significant decrease in proliferation under control conditions, 
probably because a transient reduction of Ago2 may not be sufficient to impact on basal 
proliferation. The level of miR-675-5p and -3p is tightly linked to the expression of H19 during 
the entire postnatal period. However, blockade of miR-675-5p or of miR-675-3p does not affect 
proliferation of newborn β-cells, indicating that H19 is acting via a different mechanism. In 
skeletal muscle, H19 act by sequestering let-7 (31; 49). Several observations in this study suggest 
that a similar mechanism may operate in β-cells. Indeed, blockade of let-7 increases adult β-cell 
proliferation and removal of two let-7 binding sites in the sequence of H19 reduces the 
proliferative capacity of the lncRNA. Our data do not exclude the interaction of let-7 with other 
domains of H19 or the binding of other miRNAs. The repressive activity of let-7 is higher in 
adult rat islets, which contain much less H19 compared to newborn islets. Since the level of most 
let-7 family members is not modified upon β-cell maturation (10), these findings suggest that 
H19 may control the availability of let-7. A general schema summarizing the proposed role of 
H19 in the regulation of β-cell proliferation is shown in Fig.8. Our model does not preclude the 
existence additional mechanisms through which H19 can modulate β-cell proliferation. Indeed, 
H19 may regulate enhancer and promoter activities, resulting in changes in the expression of 
neighboring genes such as Igf2, Cdkn1c, Kcnq1 and/or play important roles in the control of 
chromatin structure and of the imprinting regions. 
Our data provide congruent grounds for the idea that H19 sustains β-cell expansion in newborns 
and is required to achieve an adequate postnatal β-cell mass. Thus, exposure to environmental 
conditions during gestation affecting the expression of H19 could potentially result in a β-cell 
mass insufficient to cover the organism needs. Indeed, we found that the level of H19 is reduced 
in the islets of offspring from dams on LP diet throughout gestation and lactation and that display 
an increased risk of impaired glucose tolerance and type 2 diabetes in adult life (35). Consistent 
with these observations, reduced H19 levels were previously observed in islets from offspring of 
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gestational diabetes mellitus (50), another adverse intrauterine condition linked to reduced β-cell 
proliferation and diabetes susceptibility at adulthood (51). 
Adult β-cells undergo very little turnover and have low basal replication rates, which sustain 
metabolic homeostasis under normal conditions. However, pregnancy, obesity and β-cell 
recovery after injury are examples in which the systemic demand for insulin increases. To 
successfully compensate for the relative insulin deficiency that occurs during these metabolically 
pressured conditions, both proliferative and survival pathways are activated in insulin-secreting 
cells, to maintain blood glucose homeostasis and prevent the onset of diabetes (5). In this study, 
we observed the upregulation of H19 in different mouse models characterized by compensatory 
β-cell mass expansion in response to obesity and insulin resistance. These findings suggest that 
restoration of higher levels of H19 at adulthood in response to obesity associated insulin 
resistance may contribute to the expansion of the β-cell mass to counterbalance the diminished 
sensitivity of insulin target tissues and to prevent the onset of diabetes. Future studies involving 
the generation of gain and loss of function mice models will be needed to corroborate this 
hypothesis.  
Taken together, our observations uncover an important role for H19 in the control of newborn 
and adult rodent β-cell proliferation and shed new light on the mechanisms potentially 
contributing to diabetes susceptibility in the offspring of dams on deleterious dietary conditions 
during pregnancy and lactation. The level of H19 was reported to be higher in β-cells of young 
children compared to those of adult donors, indicating that similar changes may occur in humans 
(52). Moreover, despite differences in the nucleotide sequence we obtained evidence that human 
H19 can exert proliferative effects similar to rat H19. However, the mechanisms driving rodent β-
cell replication are often challenging to translate to humans. Thus, careful examination of the 
impact of H19 in primary human β-cells will be required before drawing definitive conclusions 
about the role of this non-coding RNA in humans.  
Future efforts will be needed to fully capture the complexity of the events triggering 
compensatory β-cell expansion seen under physiological (pregnancy) and pathophysiological 
(obesity) conditions. This knowledge will contribute to the design of novel means to combat β-
cell failure occurring in type 2 diabetes. 
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FIGURE LEGENDS 
Fig.1) Comparison of lncRNA expression between 10-day old and adult rat islets and 
regulation of H19 expression. (a) Volcano Plot representing the lncRNAs differentially 
expressed between P10 and adult islets. Up- or downregulated transcripts are depicted in red 
(nominal P<0.05, Fold change ≥│2│). H19 is indicated by the arrow. (b) Selected lncRNA with 
p-value, fold change, regulation and type.  The expression of H19 and E2F1 was measured by 
qRT-PCR in P10 and adult islets (c) or FACS-sorting purified β-cells (d). (e) Expression of H19 
and E2F1 in islets at the indicated ages was determined by qRT-PCR, normalized to 18S and 
expressed in fold change vs. P1. (f) Dissociated P10 rat islet cells were transfected with a siRNA 
against GFP or E2F1 for 48h. The expression of H19 was measured by qRT-PCR and expressed 
as fold change compared to control. The results are means±SEM of three (d) or four (c,e,f) 
independent experiments per group. *p<0.05, **p<0.01, ***P<0.001, ****P<0.0001 were 
determined by Student’s t-test or by one-way ANOVA with a Dunnett post-hoc test when more 
than 2 sets of data were analyzed. 
Fig.2) Functional role of H19 in β-cells. INS832/13 cells (a,b,c,d) or dissociated adult rat islet 
cells (f) were transfected with a control plasmid (pcDNA3) or a plasmid allowing the expression 
of H19 for 48h. (a,f) The fraction of proliferating cells was determined by scoring Ki67 positive 
cells. (b) Cell death was assessed by scoring the cells displaying pycnotic nuclei. The cells were 
incubated for the last 24h without or with a mix of cytokines. (c) Insulin secretion and insulin 
content (d) were measured by ELISA after 45 min of incubation with either 2mM or 20mM of 
glucose. (e) Dissociated P10 rat islet cells were transfected with a siRNA against GFP or H19. 
The fraction of proliferating insulin-expressing cells was determined by scoring Ki67 positive 
cells. The results are the means+SEM of three (b,e), four (f) five (c,d) or seven (a) independent 
experiments. Statistical differences from control conditions were assessed by Student’s t-test or 
by one-way ANOVA with a Dunnett post-hoc test when more than two conditions were 
compared. *P<0.05. 
Fig.3)    Involvement of miRNAs in H19 action. (a) INS832/13 cells were co-transfected with a 
siRNA against GFP or Ago2 (siGFP or siAgo2) and a control plasmid (pcDNA3) or a plasmid 
overexpressing H19. 48 h later, the fraction of proliferating cells was determined by scoring Ki67 
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positive cells. (b,c) INS832/13 cells were transfected for 48 h with a control plasmid (pcDNA3) 
or a plasmid expressing H19. (d,e) Dissociated P5 rat islet cells were transfected for 48 h with a 
siRNA against GFP or H19. miR-675-5p and -3p levels were measured by qRT-PCR, normalized 
to those of miR-130b-3p and expressed in fold change vs control condition (first column for each 
graph) or P1 levels for the postnatal islet time course expression (f). (g) Dissociated P5 rat islet 
cells were transfected with a control, a miR-675-5p or -3p inhibitor or with a siRNA against GFP 
or H19. 48 h later, the fraction of proliferating insulin-expressing cells was assessed by scoring 
Ki67 positive cells. The results are means±SEM of three (a-e) or five (f) independent 
experiments. Statistical differences from control conditions were determined by Student’s t-test 
or by one-way ANOVA with a Dunnett (a,f) or Tukey (g) post-hoc test, when more than 2 sets of 
data were analyzed. *p<0.05, ***P<0.001, ****P<0.0001. 
Fig.4) Let-7 family members participate in H19 action in β-cells. (a) Dissociated P10 or adult 
islet cells were transfected with a luciferase constructs containing (blue dots) or lacking (red dots) 
eight target sites for let-7 in its 3′ UTR. Luciferase activity was measured 48 h later. (b) 
Dissociated adult rat islet cells were transfected with a control inhibitor or with anti-miRs 
blocking all let-7 family members. INS832/13 cells (c) and dissociated adult rat islet cells (d) 
were transfected with a control plasmid (pcDNA3), a plasmid overexpressing H19 or a plasmid 
overexpressing a H19 form without let-7 binding sites (H19∆). Two days later, the fraction of 
proliferating insulin-expressing cells was assessed by scoring Ki67 positive cells. The results 
correspond to the means± SEM of three (a,b,c) or four (d) independent experiments. Statistical 
differences from control conditions were calculated by Student’s t-test or by one-way ANOVA 
with a Dunnett post-hoc test when more than two sets of data were analyzed. *p<0.05. 
Fig.5) H19 induces β-cell proliferation via the activation of Akt. (a) Representative western 
blot analysis of Akt phosphorylation at Thr-308 (P-Akt) in INS832/13 cells transfected with a 
control plasmid (pcDNA3), a plasmid overexpressing H19 or a H19 form without two binding 
sites for let-7 (H19∆). (b) The Western blots were analyzed by densitometry scanning and the 
abundance of P-Akt bands was normalized to that of actin α. (c,d) INS832/13 cells or primary rat 
islet cells (e) were transfected with a control plasmid (pcDNA3) or a plasmid expressing H19. 
After 48h, cells were exposed or not for 2h to 10 µM of the Akt inhibitor (Anti-Akt; ab142088). 
(c) Representative western blot analysis of AKT phosphorylation at Ser-478 (P-Akt) and Akt 
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protein expression. (d,e) The fraction of proliferating insulin-expressing cells was assessed by 
scoring those that were positive for Ki67. The results are means±SEM of three (d,e) or four (b) 
independent experiments. Statistical differences from control conditions were assessed by 
Kruskal-Wallis test with a Dunn post-hoc test (b) or by one-way ANOVA with a Dunnett post-
hoc test (d,e). *P<0.05. 
Fig.6) Expression of H19, E2F1, miR-675-5p and miR-675-3p in islets of offspring from low-
protein diet gestation and lactation.  H19 (a), E2F1 (b), miR-675-5p (c) and miR-675-3p (d) 
islet levels were measured by qRT-PCR in P10 control rats (Control) and P10 rat offspring from 
low-protein diet during gestation (LP), normalized to those of Ppia (a,b) or miR-130b-3p (c,d) 
and expressed in fold change. The results correspond to the means±SEM of four or six different 
individuals. Statistical differences from control pups were calculated by Student’s t-test: *p<0.05.  
Fig.7) H19 participates in β-cell mass expansion under obesity associated insulin resistance 
conditions. RNA levels were measured by qRT-PCR in islets from wt/wt and ob/ob mice (a), 
from wt/db and db/db mice (b), and in islets of mice fed with a normal chow diet (ND) or with 
high fat diet: low diet responders (LDR) and high diet responders (HFD) (c,d). (e) Linear 
regression analysis between H19 levels and weight before sacrifice of mice fed with a normal or 
high fat diet. Statistical differences from control mice (wt/wt, wt/db or ND) were calculated by 
Student’s t-test (a,b), by Kruskal-Wallis test with a Dunn post-hoc test (c) or by one-way 
ANOVA with a Dunnett post-hoc test (d). F-test was performed to measure significance in e. 
*P<0.05.
Fig.8) Model representing our view on the role of H19 in the control of β-cell proliferation.
We propose a positive feedback loop, where growth stimuli activate the PI3K and trigger the 
phosphorylation of Akt. This induces the activation of cyclin/cdk complexes that phosphorylate 
Rb, causing the release and the activation of E2F1. This results in a rise in H19 expression that 
binds let-7, relieving the repression of the targets of these miRNAs and further enhancing the 
activation of the PI3K/Akt pathway and cell cycle entry. Solid arrows indicate proven 
interactions while dotted lines show putative mechanisms inferred from our observations. 
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Supplementary table 1. List of primers used for measuring RNA levels by qRT-PCR. 
Specie Primer 
name 
Sequence 
Rat Ago2-F 5’-CCAGATGAAGAACGTGCAGA-3’ 
Ago2-R 5’-CGGCAGCAATTGAAGGTTTC-3’ 
Rat c-Myc-F 5’-CGAGCTGAAGCGTAGCTTTT-3’ 
c-Myc-R 5’-CTCGCCGTTTCCTCAGTAAG-3’ 
Rat E2f1-F 5’-GGCAAACCTGGGGAATAAGC-3’ 
E2f1-R 5’-ATGGCTGTCAGTCTGTCTCC-3’ 
Mouse E2f1-F 5’-CCCTACCCAAGAGTTGCTGA-3’ 
E2f1-R 5’-TAGGAAGGACGCATACCCAC-3’ 
Rat Gapdh-F 5’-ATGGTGAAGGTCGGTGTGAA-3’ 
Gapdh-R 5’-TCTCGCTCCTGGAAGATGG-3’ 
Mouse Gapdh-F 5’-TGCACCACCAACTGCTTAGC-3’ 
Gapdh-R 5’-GGCATGGACTGTGGTCATGAG-3’ 
Rat and mouse Hprt1-F 5’-AGTCCCAGCGTCGTGATTAG-3’ 
Hprt1-R 5’-AATCCAGCAGGTCAGCAAAG-3’ 
Human Hprt1-F 5’-CCCTGGCGTCGTGATTAGTG-3’ 
Hprt1-R 5’-GCTACAATGTGATGGCCTCCC-3’ 
Rat H19-F 5’-GCCTGAGTCTCTCCGTATGG-3’ 
H19-R 5’-GAAGGAAGGTGCGTTGAACA-3’ 
Mouse H19-F 5-‘AATGGTGCTACCCAGCTCAT-3’ 
H19-R 5’-TCAGAACGAGACGGACTTAAAGAA-3’ 
Human H19-F 5’-GCACCTTGGACATCTGGAGT-3’ 
H19-R 5’-TTCTTTCCAGCCCTAGCTCA-3’ 
Rat Igf2-F 5’-GGGACGTGTCTACCTCTCAG-3’ 
Igf2-R 5’-GTAACACGATCAGGGGACGG-3’ 
Rat Ppia-F 5’-CCACCGTGTTCTTCGACATC-3’ 
Ppia-R 5’-TTGCCACCAGTGCCATTATG-3’ 
Rat 18s-F 5'-GCAAATTACCCACTCCCGAC-3' 
18s-R 5'-CCGCTCCCAAGATCCAACTA-3' 
Insulin 
Ki67
Hoechst
Insulin 
BrdU
Hoechst
Supplementary figure 1
Supplementary Fig.1. Representative images of primary rat β-cells double
positive for insulin and Ki67 (upper panels) or for insulin and BrdU (lower
panel) are indicated by the arrowheads.
Supplementary figure 2
Supplementary Fig.2. Confirmation of the downregulation of the selected genes in
dispersed P10 islet cells and INS832/13 cells. Dissociated islet cells from P10 rats (a, b)
and INS832/13 cells (c) were transfected for two days with a siRNA against GFP (control),
E2F1 (a), H19 (b) or Ago2 (c). The expression of each gene was measured by qRT-PCR,
normalized to that of Hprt1 (a), 18s (b) or actin β (c) and is presented in fold change over the
respective controls. The results are means ± SEM of four (b,c) or five (a) independent
experiments. Statistical differences were calculated by Student’s t-test: *p<0.05, **p<0.01.
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Supplementary Fig.3. c-Myc does not control H19 expression in newborn rat islets.
a) c-Myc expression was measured by qRT-PCR in the islets of P10 and adult rats (n=3).
b,c) Dissociated islet cells from five day old rats were transfected with a control siRNA or
with an siRNA against c-Myc for 72 hours. The expression of c-Myc (b) and H19 (c) was
measured by qRT-PCR, normalized to Ppia and expressed in fold changes over control.
The results are the mean + SEM of four (b) or three (c) independent experiments.
Statistical differences were determined by Student’s t-test. *p<0.05; **p<0.01.
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Supplementary figure 4
Supplementary Fig.4. Confirmation of upregulation of the indicated transcripts in
INS832/13 cells and dispersed rat islet cells. INS832/13 cells (a,b) and dissociated islet cells
from adult rats (c,d) were transfected for two days with an empty plasmid (pcDNA3) or a plasmid
allowing the expression of H19 or a H19 mutant lacking the let-7 binding sites (H19∆). The
expression of each transcript was measured by qRT-PCR, normalized to that of Gapdh and
expressed in fold change. The results are means ± SEM of three (a,b) to four (c,d) independent
experiments. Statistical differences were calculated by Student’s t-test: *p<0.05.
Supplementary Fig.5. Effect of H19 overexpression on apoptosis. INS832/13 cells were
transfected for 48 hours with a control plasmid (pcDNA3) or a plasmid expressing H19. The
cells were incubated with or without a mix of pro-inflammatory cytokines (TNFα; IL1-β and IFNγ)
for 24 hours. Cell death was assessed by TUNEL assay. The results are the means + SEM of
three independent experiments. Statistical differences from control conditions were assessed by
ANOVA analysis with Dunnett’s post-hoc. *p<0.05.
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Supplementary figure 6
Supplementary Fig.6. Confirmation of the effect of H19 silencing on neonatal β-cell
proliferation. Dissociated islet cells from 10 days old rats were transfected with a siRNA
against GFP (control) or H19 and were incubated with BrdU for 48 hours. The fraction of
proliferating insulin-expressing cells was assessed by scoring the cells double positive for
insulin and BrdU. The data correspond to the mean + SEM of three independent
experiments. Statistical difference from control condition was determined by Student’s t-
test. *p<0.05.
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Supplementary Fig.7. Expression of Igf2 after modulation of H19 levels. (a) INS832/13
cells were transfected for 48 hours with a control plasmid or a plasmid allowing the
overexpression of H19. (b) Dispersed islet cells from P10 rats were transfected with a
siRNA against GFP or against H19. The expression of Igf2 was measured by qRT-PCR,
normalized to those of Gapdh (a) or Ppia (b). The level of Igf2 under control conditions was
set to one and is indicated by the dotted line. The results are means + SEM of two (b) to
three (a) independent experiments. Statistical differences from control conditions were
assessed by Student’s t-test.
a b
Supplementary Fig.8. Effect of H19 on human β-cell proliferation. Human 1.1 B4 cells
were transfected with a control plasmid or a plasmid allowing the overexpression of human
H19 for 48 hours. (a) The expression of H19 was measured by qRT-PCR, normalized to
that of Hprt1 and expressed in fold change. (b) The fraction of proliferating cells was
assessed by scoring Ki67 positive cells. The data correspond to the means + SEM of three
(a) or four (b) independent experiments. Statistical differences from control conditions
were determined by Student’s t-test. *p<0.05.
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Supplementary Fig.9. Confirmation of the downregulation of selected miRNAs in
INS832/13 and rat islet cells. Dissociated islet cells from P5 rats (a,b), adult rats (d,e) and
INS832/13 cells (c) were transfected with a control anti-miR (anti-control) or with anti-miR
directed against miR-657-5p (a), miR-675-3p (b), let-7a (c,d) or all let-7 family members (e).
The expression of each miRNA was measured by real-time PCR and expressed in fold
change. The results are means of two (d), three (b,c,e) or four (a) independent experiments
and statistical differences were calculated by Student’s t-test: *p<0.05, **p<0.01, ***P<0.001,
****p<0.0001.
%
 o
f 
K
i6
7
+
c
e
ll
s
a
n
t i
-c
tr
l
a
n
t i
- l
e
t7
a
0 .0
0 .5
1 .0
1 .5
2 .0 *
%
 o
f 
K
i6
7
+
/ 
In
s
 +
 c
e
ll
s
a
n
t i
-c
tr
l
a
n
t i
- l
e
t7
a
0 .0
0 .5
1 .0
1 .5
2 .0
Supplementary Fig.10. Effect of a specific inhibitor of anti-Let-7a on β-cell
proliferation. INS832/13 (a) and dissociated adult rat islet cells (b) were transfected
with a control inhibitor or with an anti-miR specifically blocking let-7a. Two days later,
the fraction of proliferating insulin-expressing cells was assessed by scoring Ki67
positive cells. Statistical differences from control conditions were assessed by
Student’s t-test. * p<0.05
a b
Supplementary figure 10
Supplementary figure 11
Supplementary Fig.11. Main potential binding sites for let-7 present in the rat
H19 sequence. Representative binding sites for seven let-7 isoforms. Red letters
show the seed sequence of let-7.
Supplementary figure 12
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CATCTGGAGTCTGGCAGGAGTGTTGAAGGACTGAGGGGCTAGCTCGGGCAGGGCAAAGGCAGCAGGACCTGGGAGG
AAGGAGCATGGTGTGGTTCCCAGGCATTGCAGAGGCTGGAAAACATCGGTGTGGGGTTGAAGGGCCTGAGCTAGGG
TTGGAGAGGAACGGGGAGCCAGACATTCATCCCGGTCACTTTTGGTTACAGGACGTGGCGGCTGGTCGGATACAGG
GGAGCTGCTGGGAAGGGTTCGACCCCAGACCTGGGCAGTGAAGGTGTAGCTGGCAGCGGTGGGCAGGTGAGGACCG
CCGTCTGCTGGGCAGGTGAGTCTCCTTCTTCTCTCTTGGCCTCGCTGCACTGACCTTCTAAAAGGTTTAGAGAGCG
AGGCCGCTGAGAAGAAGCAGCTGACCTCCCAACAGAATGGCACATAGAAAGGCAGGACAGTTAGCAAAGGAGACAT
CGTCTCGGGGGGAGCCGAGACAGAACAAGGCTGGGGGACCATTGGGCACCCCGGAGTGGAAAGAGCTTTTAGAGAG
AAGATAGAAGAGGTGCAGGGCTGCCAGTCAAGACTGAGGCTGCTGCCTCCAGGCAAGTGATAGGAGGCCTTGGAGA
CAGTGGCAGAGACTATGGGATCCAGCAAGAGCAGAAGCATTCTAGGCTGGGGTCAAACAGGGCAAGATGGGGGTCA
CAGGACACAGATGGGTCCCCAGCCGCCACCACATCCCACCCACCGTAATTCATTTAGAAGCAGGTTCAAGAGTGGC
TCTGGCAGGGCCTTCTGAGGCCTTTGCCAGAGCTTCGATGGCCGGAGAACGGGAAAGAAGGGCAGTGCAGGGTGTC
AACAGGAAGGGAACGGGGGCTGCAGGTATCGGACTCCAGAGGGATTTTACAGCAAGGAGGCTGCAGTGGGTCCAGC
CTGCAGACACACCATTCCCATGAGGCACTGCGGCCCAGGGACTGGTGCGGAAAGGGCCCACAGTGGACTTGGTGCA
CTGTATGCCCTAACCGCTCAGTCCCTGGGTCTGGCATGACAGACAGAACATTTCCAGGGGAGTCAAGGGCACAGGA
TGAAGCCAGACAAGGCGAGGCAGGTGGGGCAGAATGAATGAGCTTTCTAGGGAGGGAGGTTGGGTGCAGGTAGAGC
GAGGTAAAGCAGCTGGGGTGGTGAGCCAGCGAGGCACTGGCCTCCAGAGTCCGTGGCCAAGGAGGGCCTTGCGGGC
GGCGACGGAGCAGTGATCGGTGTCTCGGAGAGCTCGGACTGGAGACTAGGCCAGGTCTCTAGCAGAAGTGGATGTG
CCTGCCAGTCACTGAAGGCGAGGATGACAGGTGTGGTCAACGTGATAGAAAGACATGACATGGTCCGGTGTGATGG
AGAGGACAGAAGGACAGTCATCCAGCCTTCCTGAACACCGTGGGCTGGTGCCGTGGGACACTGCCGTAGAAGCCGT
CTGTTCTTTCCTTTGCCCAAAGAGCTAACACATCTCTGCTGCTCTCTGGATCCTCTTCCCATACAACTTGAACCCT
CAAGATGAAAGAAATGGTGCTACCCAGCTCATGTCTGGGCCTTTGAATCCGGGGACTTCTTTAAGTCCGTCTAGTT
CTGAATCAAGAATATGCTGCACTCAGAACACTACACTACCTGCCTCAGGAATCGGCTCGAAGGTAAAGCTGAAGGA
ACAGACGGTGACAACATCTTGAAAGAGCAGACCCACACAGCACCCACCCACCCCTGAGACTCCATCTTCATGGCCA
ACTAACTCTGCCTGGCCCGGGAGACCACCACCCACATCATCCTGGAGCCAAGCCTCTAGCCCGGGATGACTTCATC
ATCTCCCTCCTGTCTTTTTTCTTCTTCCTCCTTTCCTGTAACTCVTTTCTTTCCTTTTGTTCCTTCTCTGCTTGAG
AGACTCAAAGCATCCGTGACTCTGCTCCCCCACTCACCCCTTTTGAATTTGCACTAAGTCGATTGCACTGGTTTGG
AGTCCCGGAGATAGCCTGAGTCTCTCCGTATGGATGTATACAGCGAGTGTGTAGGCCCCTTTGGCTATGCTGCCCC
AGTGCCCGCCCGTCATCCACTTCTGTCTGAGGGCAACTGGGTGTGGCCGTGCGCTTGAGGCCTCACCTTCCCCTTG
CCTAGTCTGGAAGCAGTTCCATCATAAAGTGTTCAACGCACCTTCCTTCATCCTTTGTCCCTCCTCACCAGGGCCT
CACCAGAGGTCCTGGGTCCACCAATAAATACAGTTACAGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAA
Supplementary Fig.12. Predicted let-7 binding sites present in H19. The green sequence
indicates the binding site for let-7a, let-7d, let-7f and let-7i; and the blue sequence that for let-
7b, let-7c and let-7e. Other possible let-7 binding sites in the H19 sequence are shown in
red. The H19∆ mutant lacks the green and blue sequences.
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Supplementary Fig.13. Akt protein level after overexpression of H19 or of the
H19∆ mutant. (a) Representative western blot of Akt protein in INS832/13 cells
transfected with a control plasmid (pcDNA3), a plasmid overexpressing H19 or the
H19 mutant lacking the two main binding sites for let-7 (H19∆). (b) The intensity of
Western blot bands of Akt were determined by densitometric scanning and were
normalized to that of actin α. The results are means ± SEM of four independent
experiments.
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Supplementary Fig.14. The proliferative effect of H19 necessitates the activation of
PI3K. INS832/13 cells were transfected with a control plasmid (pcDNA3) or a plasmid
overexpressing H19. PI3K activity was or not inhibited during 36 hours with 20 µM of the
PI3K inhibitor (LY294002). Phosphorylation at Thr-308 of Akt (a downstream target of
PI3K) was assessed by western blotting (a). The fraction of proliferating cells was
assessed by scoring Ki67 positive cells (b). The data correspond to the means + SEM of
three independent experiments. Statistical differences from control conditions were
assessed by one-way ANOVA with a Tukey’a post-hoc test. *p<0.05, **<0.01.
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Supplementary figure 15
Supplementary Fig. 15. Expression of let-7a in the islets of the offspring from
dams on a low-protein diet during gestation. Let-7a levels were measured by qRT-
PCR in P10 control rats (control pups) and in P10 rats from dams on a low-protein diet
during gestation and lactation (LP pups). The results are expressed as 2-ct values and
are the means ± SEM of 4 and 6 animals. Statistical differences from control pups were
calculated by Student’s t-test: *p<0.05.
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